Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT017 (glenzocimab) add-on to standard of care for acute ischemic stroke
NL-OMON49177Phase 2Withdrawn
- Sponsor
- Acticor Biotech
- Start
- Jan 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glenzocimab in ischemic stroke (7 arms), sponsored by Acticor Biotech. Primary endpoints: Incidence of intracranial hemorrhage and Adverse events and treatment-emergent adverse events. Planned start Jan 2021; status: withdrawn.
02
Drugs
glenzocimab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NL-OMON49177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49177.